Antidiabetic activity of N-(6-substituted-1,3-benzothiazol-2-yl)benzenesulfonamides

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 9, 2008, Pages 2871-2877

  Moreno Díaz, Hermenegilda ^a   Villalobos Molina, Rafael ^b   Ortiz Andrade, Rolffy ^a   Díaz Coutiño, Daniel ^c   Medina Franco, Jose Luis ^d   Webster, Scott P ^e   Binnie, Margaret ^e   Estrada Soto, Samuel ^a,b   Ibarra Barajas, Maximiliano ^b   León Rivera, Ismael ^c   Navarrete Vázquez, Gabriel ^a,b  

^a UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c CENTRO DE INVESTIGACIONES QUÍMICAS   (Mexico)

^d TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Benzothiazole; Diabetes; Streptozotocin nicotinamide model

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; BENZENESULFONAMIDE DERIVATIVE; GLIBENCLAMIDE; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRON TRANSPORT; EMBRYO; ENZYME INHIBITION; EXPERIMENTAL MODEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYDROGEN BOND; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; STREPTOZOCIN DIABETES; STRUCTURE ANALYSIS; TREATMENT OUTCOME;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; AMINO ACID SEQUENCE; BINDING SITES; BLOOD GLUCOSE; CELL LINE; ENZYME INHIBITORS; HUMANS; HYDROGEN BONDING; HYPOGLYCEMIC AGENTS; KIDNEY; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

RATTUS;

EID: 43049119332     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.03.086     Document Type: Article

References (32)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Diabetes Care 27 (2004) 1047
2. Hogan P., Dall T., and Nikolov P. Diabetes Care 26 (2003) 917
3. Krentz A., and Bailey C. Drugs 65 (2005) 385
4. Sarabu R., and Tilley J. Ann. Rep. Med. Chem. 40 (2005) 167
5. Alberts P., Engblom L., Edling N., Forsgren M., Klingstrom G., Larsson C., Ronquist-Nii Y., Ohman B., and Abrahmsen L. Diabetologia 45 (2002) 1528
6. Seckl J.R., and Chapman K.E. Eur. J. Biochem. 249 (1997) 361
7. Seckl J.R., and Walker B.R. Endocrinology 142 (2001) 1371
8. Webster S.P., Ward P., Binnie M., Craigie E., McConnell K.M.M., Sooy K., Vinter A., Seckl J.R., and Walker B.R. Bioorg. Med. Chem. Lett. 17 (2007) 2838
9. Wamil M., and Seckl J.R. Drug Discovery Today 12 (2007) 504
10. Wang M. Curr. Opin. Invest. Drugs 7 (2006) 319
11. Fotsch C., Askew B.C., and Chen J.J. Expert Opin. Ther. Patents 15 (2005) 289
12. Webster S.P., and Pallin T.D. Expert Opin. Ther. Patents 17 (2007) 1407
13. Barf T., Vallgarda J., Emond R., Haggstrom C., Kurz G., Nygren A., Larwood V., Mosialou E., Axelsson K., Olsson R., Engblom L., Edling N., Ronquist-Nii Y., Ohman B., Alberts P., and Abrahmsen L. J. Med. Chem. 45 (2002) 3813
14. Su X., Vicker N., Ganeshapillai D., Smith A., Purohit A., Reed M.J., and Potter B.V. Mol. Cell Endocrinol. 248 (2006) 214
15. Olson S., Aster S.D., Brown K., Carbin L., Graham D.W., Hermanowski-Vosatka A., LeGrand C.B., Mundt S.S., Robbins M.A., Schaeffer J.M., Slossberg L.H., Szymonifka M.J., Thieringer R., Wright S.D., and Balkovec J.M. Bioorg. Med. Chem. Lett. 15 (2005) 4359
16. Boyle C.D., Kowalski T.J., and Zhang L. Ann. Rep. Med. Chem. 41 (2006) 127
17. Stepanchikova A.V., Lagunin A.A., Filimonov D.A., and Poroikov V.V. Curr. Med. Chem. 10 (2003) 225
18. Poroikov V.V., Filimonov D.A., Borodina Y.V., Lagunin A.A., and Kos A.. J. Chem. Inf. Comput. Sci. 40 (2000) 1349
19. Poroikov V.V., and Filimonov D.A. J. Comput. Aided Mol. Des. 16 (2002) 819
20. 4. The solvent was evaporated in vacuo and the precipitated solids were recrystallized from an appropriate solvent or purified by column chromatography.
21. 2)
22. 2 for 2 h. The assay solutions were transferred to a scintillation microplate and mixed with a solution of antimouse YSi SPA beads and anticortisol antibody in assay buffer (50 mM Tris-HCl, pH 7.0; 300 mM NaCl, 1 mM EDTA, 5% glycerol). The plate was incubated for 2 h at room temperature and read on a scintillation counter. The percentage of inhibition was determined relative to a non-inhibited control.
23. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. Nucleic Acids Res. 28 (2000) 235. http://www.rcsb.org/pdb/home/home.do Website:
24. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. J. Mol. Biol. 267 (1997) 727
25. Chemical Computing Group Inc., 1255 University Street, Montreal, Quebec, Canada H3B 3X3, 2005. Molecular Operating Environment (MOE). http://www.chemcomp.com.
26. Humphrey W., Dalke A., and Schulten K. J. Mol. Graphics 14 (1996) 33
27. Website: http://www.ibmh.msk.su/PASS.
28. Marwaha A., Goelb R.K., and Mahajana M.P. Bioorg. Med. Chem. Lett. 17 (2007) 5251
29. Masiello P., Broca C., Gross R., Roye M., Manteghetti M., Hillaire-Buys D., Novelli M., and Ribes G. Diabetes 47 (1998) 224
30. Ortiz-Andrade R.R., Rodri{dotless}́guez-López V., Garduño-Rami{dotless}́rez M.L., Castillo-España P., and Estrada-Soto S. J. Ethnopharmacol. 101 (2005) 37
31. x were the glycemia values at +1, +3, +5, and +7 h, respectively. All values were expressed as means ± SEM. Statistical significance was estimated by analysis of variance (ANOVA), p < 0.05 and p < 0.01 implies significance.
32. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. 23 (1997) 3